Evaluating CAR T-Cell Therapy Recruitment & Efficacy With Organ-On-A-Chip Technology

Chimeric antigen receptor (CAR) T-cell therapy holds significant potential as a treatment option for various human cancers. While there are several FDA-approved CAR T therapies for liquid tumors, adapting this approach successfully to treat solid tumors remains a considerable challenge.

One of the primary obstacles in targeting solid tumors with CAR T cells is their distinct microenvironment. To effectively eradicate solid tumor cells, CAR Ts need to navigate out of the vasculature at the tumor site, penetrate deeply into the tumor, lock in with tumor-specific antigens, and ultimately, kill the cancer cells. This intricate and lengthy process is not easily replicated by conventional models due to their simplicity.

Emulate's Organ-Chips offer a solution to these challenges by facilitating a more human-relevant and comprehensive recapitulation of immunotherapy efficacy. In this webinar, Chris Carman, Ph.D., presents data from proof-of-concept studies demonstrating how Organ-Chips can be employed to assess the efficacy of CAR T-cell therapies. These chips provide a platform that integrates both the recruitment and cytotoxic functions of CAR T cells.